Dsm International B.V.
recently revealed that they own 27.7% of Amyris, Inc. (NASDAQ:AMRS) in a Form 13D disclosure that was filed with the Securities and Exchange Commission (SEC) on Monday, July 17th. The investor owns 7,936,232 shares of the stock valued at approximately $32,062,377. The reporting parties listed on the disclosure included DSM International BV and Koninklijke DSM NV. The disclosure is available through EDGAR at this link.
Dsm International B.V.
provided the following explanation of their ownership:
Warning: file_get_contents(): php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6
): failed to open stream: php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6
Separately, Carl Domino Inc raised its stake in Amyris by 37.4% in the first quarter. Carl Domino Inc now owns 201,925 shares of the biotechnology company’s stock worth $107,000 after buying an additional 54,925 shares during the period.
Amyris, Inc. (AMRS) traded up 2.28% on Thursday, hitting $4.04. The stock had a trading volume of 146,148 shares. Amyris, Inc. has a 1-year low of $2.63 and a 1-year high of $18.15. The firm’s market capitalization is $80.01 million. The company’s 50 day moving average is $3.38 and its 200-day moving average is $6.40.
Amyris (NASDAQ:AMRS) last issued its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($1.95) earnings per share for the quarter, missing the consensus estimate of ($1.35) by $0.60. The company had revenue of $13 million for the quarter, compared to the consensus estimate of $32.30 million. During the same quarter last year, the company posted ($2.55) earnings per share. The firm’s revenue was up 47.7% compared to the same quarter last year. On average, analysts forecast that Amyris, Inc. will post ($3.98) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Amyris, Inc. (NASDAQ:AMRS) Stake Owned by Dsm International B.V.” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.com-unik.info/2017/07/27/dsm-international-b-v-declares-ownership-of-27-7-stake-in-amyris-inc-nasdaqamrs-updated.html.
A number of research firms recently commented on AMRS. Zacks Investment Research lowered Amyris from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. HC Wainwright set a $15.00 price objective on Amyris and gave the company a “buy” rating in a research report on Wednesday, June 7th. Finally, ValuEngine lowered Amyris from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Two research analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. Amyris presently has an average rating of “Hold” and an average target price of $31.13.
In other Amyris news, Director Patrick Y. Yang acquired 300,000 shares of Amyris stock in a transaction that occurred on Friday, May 19th. The shares were bought at an average price of $0.29 per share, with a total value of $87,000.00. Following the completion of the purchase, the director now directly owns 153,000 shares in the company, valued at approximately $44,370. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 11.30% of the company’s stock.
Amyris Company Profile
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
What are top analysts saying about Amyris Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amyris Inc. and related companies.